FDA Oversight By House To Focus On User Fees, Compounding Law
This article was originally published in The Tan Sheet
Executive Summary
Among the Energy and Commerce Committee’s priorities are ensuring correct implementation of the generic drug and biosimilar user fee programs, whose launches have experienced some hiccups.